Targeting CD70 with iPSC-Derived CAR-NK Cell Therapy Background and Objectives of the Study Over the past decade, cellular therapy for cancer has revolutionized traditional treatment concepts by introducing the idea of a “living drug.” In particular, chimeric antigen receptor T cell (CAR-T) therapy has drastically improved the efficacy of immunothe...

Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...

Spatiotemporal Regulation of KLF2 and T-bet by Eomesodermin During NK Cell Development I. Research Background Natural Killer (NK) cells are important cells in the immune system, capable of recognizing and killing tumor cells and pathogen-infected cells. The generation and development of NK cells depend on the gradual acquisition of a series of spec...

Immunoglobulin Superfamily Ligand B7H6 Enables T Cell Responses under NK Cell Surveillance Background In the field of immunology, understanding the mechanisms regulating T cell immunity is crucial for developing effective therapies for diseases related to T cell dysfunction, such as autoimmune diseases, chronic infections, and cancer. T cells media...

Tumor-Associated NK Cells Drive MDSC-Mediated Tumor Immune Tolerance via the IL-6/STAT3 Axis — Research by Neo et al. In recent years, researchers have delved deeply into the mechanisms of tumor immune escape to improve the success rate of cancer immunotherapy. The accumulation of CD8 T cells in the tumor microenvironment is a critical determinant ...